By month 4 (week 16), over 85% of patients report minimal to no side effects
Astroglial FMRP-dependent translational down-regulation of mGluR5 underlies glutamate transporter GLT1 dysregulation in the fragile X mouse
No, quality is variable and unverified
Post-infection gut dysbiosis drives systemic inflammation, leaky gut, and immune dysregulation all of which amplify fatigue, cognitive impairment, and mood instability.3 BPC-157 has been shown in multiple animal studies to: Accelerate healing of the intestinal epithelium4 Reduce gut inflammation and restore tight junction integrity5 Modulate the vagus nerve, which connects gut function to brain and immune signaling6 For long COVID patients dealing with GI symptoms, food intolerances, or fatigue that tracks with gut dysfunction, this mechanism is directly relevant
The compounded medication is not FDA-approved and is not FDA-reviewed for safety, effectiveness, or quality